Abbott India Q1 Results Revenue Up 5.32% YoY and 8.27% QoQ

Abbott India Q1 Results: Abbott India's Q1 financial results for the fiscal period ending in June 2024 show a strong performance compared to both the previous quarter (March 2023) and the same quarter last year (June 2023). The company’s total revenue increased by 8.27% from March 2023, reaching ₹1,557.61 crores. This is also a 5.32% rise from the revenue in June 2023.

Abbott India’s expenses for selling, general, and administrative activities grew by 10.89% compared to the previous quarter, showing that the company is investing more in these areas. However, depreciation and amortization costs increased slightly by 0.99%, which indicates a small rise in the cost of using the company’s assets over time. Other operating expenses decreased slightly compared to March 2023 but were still higher than in June 2023.

Abbott India’s Total operating expenses went up by 5.12%, but despite this, Abbott India’s operating income saw a significant jump of 19.69% from the last quarter, reaching ₹372.64 crores. This shows that the company is managing its costs effectively and increasing its profits.

Abbott India’s Net income before taxes rose by 12.20%, and after taxes, the net income increased by 14.27% compared to the previous quarter, reflecting overall profitability. The diluted normalized earnings per share (EPS) also grew by 14.26%, showing that the company's earnings per share have improved significantly. This overall growth highlights Abbott India's strong financial health and effective management during this period.

Here are Abbott India's Q1 financial results for the fiscal period ending in June 2024, with comparisons to the previous quarter and the same quarter last year. 

All figures are in crores, except for per share values:

Source: Here 

For More Q1 Results check our Twitter Page

Visit our website for more Q1 results

Abbott India Q1 Results

Abbott India recently shared its financial results for the quarter that ended on June 30, 2024. The report compares these results with previous periods, including the last quarter (March 31, 2024) and the same quarter from the previous year (June 30, 2023).

During this quarter, Abbott India earned ₹1,557.61 crores from its main operations, which was higher than the ₹1,438.63 crores they earned in the previous quarter. They also made some additional income from other sources, amounting to ₹67.33 crores, though this was slightly less than what they made in the previous quarter.

The total income for the quarter was ₹1,624.94 crores, showing an increase from the previous quarter's ₹1,519.78 crores. To achieve this, Abbott India had to spend money on various things, like raw materials and purchases, which totaled ₹1,187.72 crores. This was also higher than their expenses in the previous quarter.

After all the expenses, the profit before tax for the quarter was ₹437.22 crores, an increase compared to ₹389.68 crores in the last quarter. The final profit, after accounting for taxes, was ₹328.01 crores, which is again higher than the profit in the previous quarter. The company's earnings per share, a measure of how much profit is made for each share, increased to ₹15.42.

The provided document appears to be a financial statement for a company, showing unaudited results for the quarter ended June 30, 2024. 

Here’s a simplified breakdown of some key figures and comparisons:

Abbott India Financial Performance

The table provides key financial details about Abbott India’s stock. The company has a market capitalization of ₹63,824 Crores, indicating its total value in the market. The current stock price is ₹30,035, with the highest price over the past year being ₹30,521 and the lowest at ₹21,907. The Price-to-Earnings ratio (P/E) is 51.5, showing how much investors are willing to pay for each unit of earnings. The book value per share is ₹1,741, meaning this is the net worth of each share.

Here's the information in a table format:

Quarterly Results 

Abbott India's financial results for three quarters: December 2023, March 2024, and June 2024. In December 2023, Abbott's sales were ₹1,437 crores, with expenses of ₹1,049 crores, leading to an operating profit of ₹388 crores. Their operating profit margin was 27%. By March 2024, sales slightly increased to ₹1,439 crores, but expenses also rose to ₹1,109 crores, reducing the operating profit to ₹330 crores and lowering the margin to 23%.

Here is the table for the quarters Dec 2023, Mar 2024, and Jun 2024:

(Figures in Rs. Crores)

About Abbott India 

Abbott India, a subsidiary of Abbott Laboratories, is a major pharmaceutical company headquartered in Mumbai, India. The company has been dedicated to improving health in India since 1910. Abbott India offers a wide range of high-quality products, including nutritional supplements, diagnostic tools, branded generic medicines, and devices for diabetes and vascular health. The company’s products cover many areas of healthcare such as women’s health, digestive health, heart care, metabolic disorders, and general medical care.

As one of the fastest-growing pharmaceutical companies in India, Abbott India is known for its commitment to providing reliable and effective healthcare solutions. The company has a strong focus on both global and local needs, tailoring its products and services to meet the specific requirements of the Indian market. 

Abbott India’s in-house teams handle product development, manufacturing, and customer service, ensuring that all products meet high international quality standards. By combining advanced science and technology with a deep understanding of local needs, Abbott India aims to offer exceptional healthcare solutions and support to people across the country.